4.8 Article

CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer

期刊

NATURE COMMUNICATIONS
卷 13, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41467-022-30375-8

关键词

-

资金

  1. Fondazione Umberto Veronesi (FUV)
  2. AIRC fellowship
  3. Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 23060, IG 11904, IG 15538, IG 2016]
  4. Italian Ministry of University and Scientific Research (MIUR)
  5. Italian Ministry of Health [RF-2013-02358446]
  6. Italian Ministry of University and Scientific Research (MIUR) PRIN [20177E9EPY_002, 202032AZT3_004]
  7. University of Milan -PSR 2020
  8. Italian Ministry of Health

向作者/读者索取更多资源

The overexpression of CDK12 in breast cancer promotes tumorigenesis and makes the cancer cells vulnerable to therapies targeting folate one-carbon metabolism. CDK12 overexpression is associated with early tumor onset and metastasis and is linked to hyperactivation of the serine-glycine-one-carbon network. CDK12-overexpressing breast tumors show positive response to chemotherapy targeting CDK12-induced metabolic alterations, while being refractory to other types of chemotherapy.
Finding biomarkers for targeted therapy is a promising approach to treat cancer. Here, the authors show that in breast cancer preclinical models and patients, CDK12 promotes tumourigenesis but induces selective vulnerability to therapies that target folate one-carbon metabolism. Cyclin-dependent kinase 12 (CDK12) overexpression is implicated in breast cancer, but whether it has a primary or only a cooperative tumorigenic role is unclear. Here, we show that transgenic CDK12 overexpression in the mouse mammary gland per se is sufficient to drive the emergence of multiple and multifocal tumors, while, in cooperation with known oncogenes, it promotes earlier tumor onset and metastasis. Integrative transcriptomic, metabolomic and functional data reveal that hyperactivation of the serine-glycine-one-carbon network is a metabolic hallmark inherent to CDK12-induced tumorigenesis. Consistently, in retrospective patient cohort studies and in patient-derived xenografts, CDK12-overexpressing breast tumors show positive response to methotrexate-based chemotherapy targeting CDK12-induced metabolic alterations, while being intrinsically refractory to other types of chemotherapy. In a retrospective analysis of hormone receptor-negative and lymph node-positive breast cancer patients randomized in an adjuvant phase III trial to 1-year low-dose metronomic methotrexate-based chemotherapy or no maintenance chemotherapy, a high CDK12 status predicts a dramatic reduction in distant metastasis rate in the chemotherapy-treated vs. not-treated arm. Thus, by coupling tumor progression with metabolic reprogramming, CDK12 creates an actionable vulnerability for breast cancer therapy and might represent a suitable companion biomarker for targeted antimetabolite therapies in human breast cancers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据